BYL-719 hydrochloride
- CAS No.
- 1584128-91-5
- Chemical Name:
- BYL-719 hydrochloride
- Synonyms
- BYL-719 hydrochloride;Alpelisib hydrochloride
- CBNumber:
- CB38054615
- Molecular Formula:
- C19H23ClF3N5O2S
- Molecular Weight:
- 477.93
- MDL Number:
- MFCD32201157
- MOL File:
- 1584128-91-5.mol
BYL-719 hydrochloride Chemical Properties,Uses,Production
Uses
Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent, orally active, and selective PI3Kα inhibitor with IC50s of 5 nM, 250 nM, 290 nM and 1200 nM for p110α, p110γ, p110δ, and p110β, respectively. Alpelisib hydrochloride (BYL-719 hydrochloride) shows antineoplastic activity[1][2].
in vivo
Alpelisib (BYL-719) (12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice; oral administration; daily) significantly reduces tumor volumes and deposition of ectopic bone matrix[3].
Alpelisib has moderate terminal elimination half-life (t1/2=2.9±0.2 h) for rat (1 mg/kg, iv)[1].
| Animal Model: | A 5-week-old female Rj:NMRI-nude mice with human HOS-MNNG osteosarcoma cells; A 5-week-old male C57Bl/6J mice with mouse MOS-J osteosarcoma cells[3] |
| Dosage: | 12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice |
| Administration: | Oral administration; daily |
| Result: | Significantly reduced tumor volumes and simultaneously reduced tumor growth. |
| Animal Model: | Female Sprague Dawley rats [1] |
| Dosage: | 1 mg/kg (Pharmacokinetic Study) |
| Administration: | I.V. |
| Result: | T1/2=2.9±0.2 hours. |
References
[1] Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8. DOI:10.1016/j.bmcl.2013.05.007
[2] Fritsch C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13(5):1117-29. DOI:10.1158/1535-7163.MCT-13-0865
[3] Gobin B, et al. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer. 2015 Feb 15;136(4):784-96. DOI:10.1002/ijc.29040
BYL-719 hydrochloride Preparation Products And Raw materials
Raw materials
Preparation Products
BYL-719 hydrochloride Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +17819995354 | marketing@targetmol.com | United States | 32291 | 58 |
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38669 | 58 | |
| TargetMol Chemicals Inc. | +17819995354 | marketing@targetmol.com | United States | 19904 | 58 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 12952 | 65 |
| Wuhan Yingnuo Pharmaceutical Technology Co., Ltd. | +86-027-59232304 15387063101 | 2881924050@qq.com | China | 10025 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24899 | 58 |
| Olix (Shanghai) Pharmaceutical Technology Co., Ltd | 17316404525 | 209533805@qq.com | China | 9976 | 58 |
| Adooq Bioscience LLC | 400-025-6535 | sales@adooq.cn | China | 6215 | 58 |
View Lastest Price from BYL-719 hydrochloride manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-10-24 | Alpelisib hydrochloride
1584128-91-5
|
US $2580.00-1970.00 / mg | 10g | TargetMol Chemicals Inc. |
-
- Alpelisib hydrochloride
1584128-91-5
- US $2580.00-1970.00 / mg
- TargetMol Chemicals Inc.